Skip to main content Skip to navigation
FITC Mouse Anti-Human TNF-α
Product Details
Down Arrow Up Arrow

BD FastImmune™
Mouse IgG1
Recombinant human TNF-a
Intracellular staining (flow cytometry)
20 μL
Phosphate buffered saline with gelatin and 0.1% sodium azide.

Preparation And Storage

The FITC and PE conjugates are each supplied in 1.0 mL of PBS. The APC conjugate is supplied in 0.5 mL of PBS. Buffered saline contains gelatin and 0.1% sodium azide. Please refer to the vial label for antibody concentration. The vial should be stored at 2° to 8°C. Conjugated forms should not be frozen and should be protected from prolonged exposure to light. Each reagent is stable for the period shown on the bottle label when stored as directed.

340511 Rev. 1
Antibody Details
Down Arrow Up Arrow

Anti-Hu–TNF-α, clone 6401.1111, is derived from a fusion of Sp2/0 myeloma cells with splenocytes from BALB/c mice immunized with recombinant human TNF-α.

Anti-Human Tumor Necrosis Factor-α (Anti-Hu–TNF-α) recognizes a 26-kilodalton (kd) transmembrane protein.

340511 Rev. 1
Format Details
Down Arrow Up Arrow
Fluorescein (FITC) is part of the BD blue family of dyes. This is a small organic fluorochrome with an excitation maximum (Ex Max) at 494-nm and an emission maximum (Em Max) at 518-nm. FITC is designed to be excited by the Blue laser (488-nm) and detected using an optical filter centered near 520 nm (e.g., a 530/30-nm bandpass filter). Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Blue 488 nm
494 nm
518 nm
340511 Rev.1
Citations & References
Down Arrow Up Arrow
View product citations for antibody "340511" on CiteAb

Development References (34)

  1. Aversa G, Punnonen J, de Vries JE. The 26-kD transmembrane form of tumor necrosis factor α on activated CD4+ T cell clones provides a co-stimulatory signal for human B cell activation. J Exp Med. 1993; 177:1575-1585. (Biology).
  2. Beutler B, Cerami A. CachectMore than a tumor necrosis factor. N Eng J Med. 1987; 316:379-385. (Biology).
  3. Beutler B, Cerami A. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Ann Rev Biochem. 1988; 57:505-518. (Biology).
  4. Birkland TP, Sypek JP, Wyler DJ. Soluble TNF and membrane TNF expressed on CD4+ T lymphocytes differ in their ability to activate macrophage antileishmanial defense. J Exp Med. 1992; 51:296-299. (Biology).
  5. Cassatella MA, Meda L, Bonora S, et al. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 β in mediating the production of IL-8 triggered by lipopolysaccharide. J Exp Med. 1993; 178:2207-2211. (Biology).
  6. Cuturi MC, Murphy M, Costa-Giomi P, et al. Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med. 1987; 165:1581-1594. (Biology).
  7. Decamps-Latscha B, Herbelin A, Nguyen AT, et al. Balance between IL-1β, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. Relationships with activation markers of T cells, B cells, and monocytes. J Immunol. 1995; 154:882-892. (Biology).
  8. Grell M, Douni E, Wajant H, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80-kDa tumor necrosis receptor. Cell. 1995; 83:793-802. (Biology).
  9. Hsu H, Shu HB, Pan MG, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996; 84(2):299-308. (Biology). View Reference
  10. Jones EY, Stuart DI, Walker NPC. Structure of tumour necrosis factor. Nature. 1989; 338:225-228. (Biology).
  11. Kehrl JH, Miller A, Fauci AS. Effect of tumor necrosis factor α on mitogen-activated human B cells. J Exp Med. 1987; 166:786-791. (Biology).
  12. Kinkhabwala M Sehajpal P, Skolnik E, et al. A novel addition to the T cell repertory, Cell surface expression of tumor necrosis factor/cachectin by activated normal human T cells. J Exp Med. 1990; 171:941-946. (Biology).
  13. Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell. 1988; 53(1):45-53. (Biology). View Reference
  14. Luettig B, Decker T, Lohmann-Matthes M-L. Evidence for the existence of two forms of membrane tumor necrosis factor: An integral protein and a molecule attached to its receptor. J Immunol. 1989; 143:4034-4038. (Biology).
  15. Martich GD, Danner RL, Ceska M, et al. Detection of interleukin 8 and tumor necrosis factor in normal humans after intravenous endotoxThe effect of anti-inflammatory agents. J Exp Med. 1991; 173:1021-1024. (Biology).
  16. Mestan J, Digel W, Mittnacht S, et al. Antiviral effects of tumour necrosis factor in vitro. Nature. 1986; 323:816-819. (Biology).
  17. Michie HR, Manogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Eng J Med. 1988; 318:1481-1486. (Biology).
  18. Old LJ. Tumor necrosis factor (TNF). Science. 1985; 230:630-632. (Biology).
  19. Ostensen ME, Thiele DL, Lipsky PE. Tumor necrosis factor-α enhances cytolytic activity of human natural killer cells. J Immunol. 1987; 138:4185-4191. (Biology).
  20. Perez C, Albert I, DeFay K, et al. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact. Cell. 1990; 63:251-258. (Biology).
  21. Rosenberg ZF, Fauci AS. Immunopathogenic mechanisms of HIV infection: Cytokine induction of HIV expression. Immunol Today. 1990; 11:176-180. (Biology).
  22. Saklatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Science. 1986; 322:547-549. (Biology).
  23. Santis AG, Campanero MR, Alonso JL, et al. Tumor necrosis factor-α production induced in T lymphocytes through the AIM/CD69 activation pathway. Eur J Immunol. 1992; 22:1253-1259. (Biology).
  24. Silberstein DS, David JR. Tumor necrosis factor enhances eosinophil toxicity to Schistosoma mansoni larvae. Proc Natl Acad Sci USA. 1986; 83:1055-1059. (Biology).
  25. Smith CA, Farrah T, Goodwin RG. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell. 1994; 76(6):959-962. (Biology). View Reference
  26. Sung SJ, Bjorndahl JM, Wang CY, et al. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med. 1988; 168:1539-1551. (Biology).
  27. Sung SJ, Bjorndahl JM, Wang CY, et al. Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. J Exp Med. 1988; 168:1539-1551. (Biology).
  28. Sypek JP, Wyler DJ. Antileishmanial defense in macrophages triggered by tumor necrosis factor expressed on CD4+ T lymphocyte plasma membrane. J Exp Med. 1991; 174:755-759. (Biology).
  29. Tartaglia LA, Goeddel DV, Reynolds C, et al. Stimulation of human T-cell proliferation by specific activation of the 75-kDa tumor necrosis factor receptor. J Immunol. 1993; 151:4637-4641. (Biology).
  30. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 1992; 13:151-153. (Biology).
  31. Thompson CB, Lindsten T, Ledbetter JA, et al. CD28 activation pathway regulates the production of multiple T-cell–derived lymphokines/cytokines. Proc Natl Acad Sci USA. 1989; 86:1333-1337. (Biology).
  32. Tracey KJ, Beutler B, Lowry SF, et al. Shock and tissue injury induced by recombinant human cachectin. Science. 1986; 234:470-474. (Biology).
  33. Wong GH, Goeddel D. Tumour necrosis factors α and β inhibit virus replication and synergize with interferons. Nature. 1986; 323:819-822. (Biology).
  34. Wright SC, Jewett A, Mitsuyasu R, et al. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients. J Immunol. 1988; 141:99-104. (Biology).
View All (34) View Less
340511 Rev. 1

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures. 


Although not required, these products are manufactured in accordance with Good Manufacturing Practices.